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Abstract
Background: Mutations in the c-KIT proto-oncogene have been implicated in the progression of
several neoplastic diseases, including gastrointestinal stromal tumors and mastocytosis in humans,
and cutaneous mast cell tumors (MCTs) in canines. Mutations in human mastocytosis patients
primarily occur in c-KIT exon 17, which encodes a portion of its kinase domain. In contrast,
deletions and internal tandem duplication (ITD) mutations are found in the juxtamembrane domain
of c-KIT in approximately 15% of canine MCTs. In addition, ITD c-KIT mutations are significantly
associated with aberrant KIT protein localization in canine MCTs. However, some canine MCTs
have aberrant KIT localization but lack ITD c-KIT mutations, suggesting that other mutations or
other factors may be responsible for aberrant KIT localization in these tumors.
Methods: In order to characterize the prevalence of mutations in the phospho-transferase portion
of c-KIT's kinase domain in canine MCTs exons 16–20 of 33 canine MCTs from 33 dogs were
amplified and sequenced. Additionally, in order to determine if mutations in c-KIT exon 17 are
responsible for aberrant KIT localization in MCTs that lack juxtamembrane domain c-KIT
mutations, c-KIT exon 17 was amplified and sequenced from 18 canine MCTs that showed an
aberrant KIT localization pattern but did not have ITD c-KIT mutations.
Results: No mutations or polymorphisms were identified in exons 16–20 of any of the MCTs
examined.
Conclusion: In conclusion, mutations in the phospho-transferase portion of c-KIT's kinase domain
do not play an important role in the progression of canine cutaneous MCTs, or in the aberrant
localization of KIT in canine MCTs.
Background
The c-KIT proto-oncogene encodes the type III receptor
tyrosine kinase KIT, which consists of an extracellular lig-
and binding domain, a transmembrane domain, a nega-
tive regulatory juxtamembrane domain and a split kinase
domain [1-3] (Figure 1). In healthy humans as well as in
dogs, c-KIT is expressed by multiple cell types including
mast cells, germ cells, melanocytes, and hematopoietic
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precursor cells [4-8]. Notably, in mast cells KIT and its lig-
and stem cell factor (SCF, also known as mast cell growth
factor) [9-12] have been shown to be involved in cell sur-
vival, proliferation, differentiation, chemotaxis, degranu-
lation, and fibronectin adhesion [10,13-17]. In human
patients, mutations in the c-KIT  proto-oncogene have
been implicated in the pathogenesis of multiple neoplas-
tic diseases, including mastocytosis, germ cell tumors, and
gastrointestinal stromal tumors (GISTs) [18-23]. The loca-
tions of these c-KIT mutations vary between the different
neoplastic diseases. The vast majority of mutations char-
acterized in human patients with mastocytosis occur at
codon 816 in exon 17, which encodes a portion of the
kinase domain of KIT [19,24,25]. Mutations in germ cell
tumors have been found in both the juxtamembrane
domain and the kinase domain of c-KIT [21,22], while
mutations in GISTs tend to occur in exon 11 of the jux-
tamembrane domain of c-KIT [23,26,27]. Despite their
variation in location both, juxtamembrane domain and
kinase domains c-KIT mutations result in a constitutively
activated KIT protein that is phosphorylated in the
absence of the ligand [18,21-23].
In recent years, c-KIT has been implicated in the patho-
genesis of canine cutaneous mast cell tumors (MCTs),
which are one of the most common neoplasms in dogs
[28-32]. Internal tandem duplications (ITDs), deletions,
and point mutations have been identified in the juxtam-
embrane domain of c-KIT in canine cutaneous MCTs [33-
35]. The reported incidence of c-KIT mutations has varied
between different studies. In two studies that screened
randomly selected cases submitted, mutations were iden-
tified in 15% of canine MCTs [35,36]. However, another
study reported c-KIT mutations in 50% of canine MCTs
that were seen in a referral oncology practice [37]. This
discrepancy in the incidence of c-KIT mutations in canine
MCTs is most likely due to the variations in case selection
between these studies with the higher percentage reflect-
ing ascertainment bias at the referral practice. Internal tan-
dem duplication c-KIT mutations are the most common
[35,38], and therefore the most extensively studied c-KIT
mutation in canine MCTs. All of the ITD mutations that
have been studied thus far have been found to produce a
constitutively activated product, thereby implicating c-KIT
in the progression of canine MCTs [33,34,39]. Previous
work by our laboratory has shown that c-KIT mutations
are significantly associated with higher histologic grade
MCTs [35], and that MCT patients with ITDs have a signif-
icantly worse prognosis as compared to patients without
ITD mutations, thereby further implicating c-KIT in the
progression of canine MCTs [36].
In addition to c-KIT mutations, aberrant KIT expression
and more specifically, the aberrant localization of KIT has
been described in canine cutaneous MCTs [40-42].
Recently our laboratory has identified 3 patterns of KIT
protein localization in canine MCTs: 1. peri-membrane
KIT localization (KIT pattern 1); 2. cytoplasmic stippling
to focal KIT localization (KIT pattern 2); 3. diffuse cyto-
plasmic KIT localization (KIT pattern 3), as shown in Fig-
ure 2. Recent studies have shown that canine MCTs that
have a primarily cytoplasmic pattern of KIT protein local-
ization (KIT patterns 2 and 3) have a significantly worse
prognosis, in terms of both their disease-free interval and
survival duration, as compared to MCTs that have a pri-
marily peri-membrane pattern of KIT localization [41].
Furthermore, we have found that ITD c-KIT mutations in
canine MCTs are significantly associated with aberrant KIT
localization in neoplastic mast cells. However, a substan-
tial number of canine MCTs have aberrant KIT localiza-
tion, but do not have ITD mutations [36]. This suggests
that additional factors, aside from ITD c-KIT mutations
may be responsible for aberrant KIT localization in neo-
plastic mast cells.
Despite the high incidence of c-KIT kinase domain muta-
tions in human patients with mastocytosis, only a total of
18 canine MCTs and 3 canine MCT cell lines have been
Schematic diagram of the receptor tyrosine kinase KIT Figure 1
Schematic diagram of the receptor tyrosine kinase KIT.BMC Cancer 2006, 6:85 http://www.biomedcentral.com/1471-2407/6/85
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evaluated for kinase domain mutations in c-KIT [33,34].
For a more detailed evaluation of possible c-KIT kinase
domain mutations in canine MCTs, we screened exons
16–20 of the phospho-transferase portion of the kinase
domain of c-KIT for mutations that may contribute to the
progression of these tumors. Additionally, in order to
determine if mutations in exon 17 of c-KIT, where the
majority of mutations occur in human mastocytosis
patients, were responsible for aberrant KIT localization,
exon 17 was screened in 18 MCTs with aberrant KIT local-
ization that lack ITD c-KIT mutations. However, no muta-
tions or polymorphisms were identified in exons 16–20
of any of the canine MCTs that were examined.
Methods
Study population
Samples from 33 canine cutaneous MCTs from 33 dogs
were obtained from archival formalin-fixed paraffin-
embedded tissues that had been submitted to the Diag-
nostic Center for Population and Animal Health at Mich-
igan State University. Single paraffin blocks with
neoplastic tissue were selected for each tumor and each
tumor was histologically graded based on the Patnaik his-
tologic grading system [43] for canine cutaneous MCTs.
DNA isolation from formalin-fixed paraffin embedded 
tissues
Tissue samples for DNA isolation were selected within the
tumor boundaries, as identified by histologic evaluation.
Approximately 2 mm3 tissue samples were obtained from
each block for DNA extraction. DNA was isolated as pre-
viously described [35,44]. In brief, 400 µl of digestion
buffer (50 mM Tris, pH 8.5, 1 mM EDTA, 0.5% Tween)
was added to each sample. Samples were heated to 95°C
for 10 minutes followed by heating in a microwave at full
power twice for 30 seconds. Samples were thoroughly vor-
texed between each heating step. 5 µl of 15 mg/ml protei-
nase K was added to each sample, and the samples were
subsequently incubated overnight at 42°C. Proteinase K
was inactivated at 95°C for 10 minutes. Samples were
then centrifuged and 200 µl of the reaction was aliquoted
for use as template in PCR.
Amplification of c-KIT exons 16–20
PCR amplification was carried out using primer pairs that
flanked exons 16, 17, 18, 19, and 20 in order to sequence
each exon in its entirety and the 10–20 nucleotides that
flank each exon (Table 1, Figure 3). Twenty-five microliter
PCR reactions were prepared with 5 µl DNA at a 1:25 dilu-
tion, 5 pmol of each primer, 0.5 units of Taq polymerase
(Invitrogen, Carlsbad, CA), and final concentrations of 80
µM dNTPs, 2 mM MgCl2, 20 mM Tris-HCl, and 50 µl KCl.
Cycling conditions for amplifying exons 16, 17, 18, and
20 were as follows: 94°C for 4 minutes; 40 cycles at 94°C
for 1 minute, 60°Cfor 1 minute, and 72°C for 1 minute;
72°C for 5 minutes. Cycling conditionswere similar for
exon 19, except a 54°C annealing temperature was used
instead of a 60°C annealing temperature. Amplified prod-
ucts were visualized by agarose gel electrophoresis on a
2% agarose gel stained with ethidium bromide.
Sequencing of c-KIT exons 16–20
Amplified products were pooled in groups of 7–10 for
DNA sequencing whenever possible, as previously
described [45]. This pool and sequence method has been
shown to allow for the detection of minor alleles at fre-
quencies as low as 5%. If clean sequences were not
obtained from pooled samples, then samples were
sequenced individually. DNA to be sequenced was sepa-
rated on a 2% agarose gel, and DNA fragments were
excised for DNA purification. DNA was purified using the
Qiaex II gel purification kit (Qiagen, Valencia, CA)
Immunohistochemical staining patterns of canine cutaneous MCTs staining with anti-KIT antibodies Figure 2
Immunohistochemical staining patterns of canine cutaneous MCTs staining with anti-KIT antibodies. A. KIT staining pattern 1: 
peri-membrane KIT protein localization; B. KIT staining pattern 2: focal or stippled cytoplasmic KIT protein localization; C. KIT 
staining pattern 3: Diffuse cytoplasmic KIT localization. Canine MCTs with KIT staining patterns 2 and 3 that lacked ITD c-KIT 
mutations were screened for mutations in c-KIT exon 17. B and C show MCTs with aberrant KIT localization that lack ITD c-
KIT mutations.BMC Cancer 2006, 6:85 http://www.biomedcentral.com/1471-2407/6/85
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according to manufacturer's protocol. DNA sequencing
was carried out using the Thermo Sequenase radiolabeled
terminator cycle sequencing kit (Amersham, Piscataway,
NJ), following manufacturer's instruction. Sequence reac-
tions were separated on a 6% denaturing polyacrylamide
gel, which was dried and exposed to BioMax MR scientific
imaging film (Kodak, Rochester, NY) for 72 hours for vis-
ualization.
DNA isolation from laser capture microdissected tumor 
samples
Eighteen MCTs with aberrant KIT localization, but no ITD
c-KIT mutations were identified as part of a previous study
[36] (figure 3. Seven micron sections of each MCT were
dehydrated and stained with hematoxylin for laser cap-
ture microdissection. 2,000–4,000 neoplastic mast cells
were extracted from each tumor sample using the Pixcell
laser capture microdissection system with Macro LCM
caps (Arcturus, Mountain View, CA). LCM caps adhered to
extracted cells were incubated inverted overnight in 50 µl
of DNA extraction buffer (10 mM Tris pH 8.0, 1 mM
EDTA, 1% Tween) and 1.5 µl of 15 mg/ml Proteinase K at
37°C. Samples were centrifuged at 1306 × g for 5 minutes,
and Proteinase K was inactivated by heating at 95°C for 8
minutes. 5 µl of DNA was used for each 25 µl reaction.
PCR reactions were prepared using primers flanking c-KIT
exon 17 as described above.
Results
Thirty-three cutaneous MCTs from 33 dogs were included
in this study. The age of these dogs ranged from 2.5–15
years with an average of 7.42 years. Twenty of the 33 dogs
were female and 13 were male. The breed distribution of
this study population included 10 boxers, 9 Labrador
retrievers, 5 golden retrievers, 1 Boston terrier, 1 Bichon
Frise and 7 mixed breed dogs. All MCTs were graded
according to the Patnaik histologic grading system for
canine cutaneous mast cell tumors [43]. Twelve of the 33
MCTs were histologic grade 1, 18 were grade 2, and 3 were
grade 3. All 33 MCTs included in this study were previ-
ously screened for mutations in the juxtamembrane
domain of c-KIT. No internal tandem duplications or
deletions were identified in the juxtamembrane domain
of c-KIT in any of the MCTs included in this study (data
not shown).
In order to identify potential activating mutations c-KIT
exons 16, 17, 18, 19, and 20, which encode the phospho-
transferase region of the kinase domain of the KIT protein,
were amplified using PCR amplification and sequenced.
Exons 16 to 20 were identical to previously published
cDNA sequences of the canine c-KIT  gene [Gen-
bank:AF448148] in all canine MCTs examined. No muta-
tions or polymorphisms were identified in c-KIT exons 16
to 20 in any of the canine cutaneous MCTs screened. One
single nucleotide polymorphism was identified at the 7th
nucleotide of intron 18 consisting of a C to A transversion.
Previous work by our laboratory has identified a correla-
tion between ITD c-KIT mutations and aberrant KIT local-
ization in canine cutaneous MCTs. However, we have also
found that a subset of canine cutaneous MCTs have aber-
rant KIT localization without having ITD c-KIT mutations
[36]. In human mastocytosis patients, mutations of c-KIT
are commonly seen in exon 17 [19,24,25]. In order to test
the hypothesis that mutations in c-KIT  exon 17 are
responsible for aberrant KIT localization in canine MCTs
that lack ITD c-KIT mutations, exon 17 was amplified and
sequenced from 18 such cases. Exon 17 was identical to
previously published c-KIT  sequences [Gen-
bank:AF448148] and no mutations or polymorphisms
were identified in exon 17 in any of the canine MCTs eval-
uated.
Discussion
This study did not identify any mutations of the phospho-
transferase domain of c-KIT in 33 canine cutaneous MCTs
examined. These findings are also supported by reports
from London et al. in which 11 MCTs were examined for
kinase domain mutations [33]. Therefore, it is highly
unlikely that the phospho-transferase domain of c-KIT
plays a role in the progression of canine MCTs. Further-
Table 1: Primers used for PCR amplification of c-KIT exons 16–20 and size of expected PCR products for each primer pair.
Exon Primer Number Direction Sequence Product Size (bp)
16 1202 Forward CTT TGA GGC TTA ATT GCT AAG AA 256
1203 Reverse ACT ATG AAC TCT AAA ATG CGC CA
17 1204 Forward ATA GCA GCA TTC TCG TGT TG 261
1205 Reverse AAC TAA AAT CCT TCA CTG GAC TG
18 1206 Forward AAC ATT GCC GGA TCT GTT GT 189
1207 Reverse AGA TGC TCT CGC CCA ACC A
19 1208 Forward GGG TCC TGC TTG CTT ATT 188
1209 Reverse AGC ATG ATC TCA AGG GAA
20 1210 Forward AGG CTA AGG GCG TTG AGG 189
1211 Reverse GCA GGG AGG TTC TAC GGC TBMC Cancer 2006, 6:85 http://www.biomedcentral.com/1471-2407/6/85
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more, mutations in exon 17 of the c-KIT proto-oncogene,
where mutations are most commonly seen in human
patients with mastocytosis [19,24,25], do not contribute
to the aberrant localization of KIT in canine cutaneous
MCTs.
The kinase domain of c-KIT is highly conserved between
humans and canines. In a comparison of the human
[Genbank: NM_000222] and canine [Genbank:
AF448148] amino acid sequences corresponding to exons
16–20, there is only a single difference in which a gluta-
mate in the human is replaced with an aspartate residue in
exon 20 of the dog, giving greater than 99% identity
between these species (figure 4). The high degree of con-
servation between the human and the dog suggests that a
change in a single amino acid of the kinase domain could
alter the function of the KIT protein, potentially produc-
ing a constitutively activated protein, as is seen in human
mastocytosis patients. However, unlike human mastocy-
tosis patients, kinase domain c-KIT  mutations do not
appear to play a role in the progression of canine MCTs.
Internal tandem duplications and deletions in the juxtam-
embrane domain of c-KIT have been identified in approx-
imately 15% of canine MCTs [36]. The internal tandem
duplication mutations are the most frequent and best
characterized c-KIT mutations in canine MCTs [35,38]. All
of the characterized ITD mutations result in a constitu-
tively activated KIT product, which is characterized by the
constitutive phosphorylation of the receptor in the
absence of ligand binding [33,34,39]. Considering the
role of c-KIT  in mast cell survival and proliferation
[10,17]and the association between ITD c-KIT mutations
and decreased disease-free interval and survival duration
of dogs [36], c-KIT appears to play a key role in the pro-
gression of canine MCTs [36]. Therefore, c-KIT may also
represent a potential therapeutic target for canine cutane-
ous MCTs [35-37,39,41,46].
Juxtamembrane domain c-KIT mutations have only been
found in approximately 15% of all canine MCTs [35,36]
and 50% of high grade MCTs [37]. We hypothesized that
phospho-transferase domain c-KIT mutations may play a
role in the progression of canine cutaneous MCTs that
lack ITD c-KIT mutations. The goal of this study was to
investigate the presence of any activating mutations in the
phospho-transferase domain of the c-KIT  proto-onco-
gene. The results of this study suggest that c-KIT mutations
of the phospho-transferase domain do not play a signifi-
cant role in the progression of canine MCTs. Since some
small molecule kinase inhibitors have shown a greater
efficacy in tumors with mutations in the target receptor
tyrosine kinase (e.g. KIT) [39,47,48], MCTs lacking c-KIT
mutations may not be as good of candidates for the treat-
ment with these drugs. Therefore, other genetic or epige-
netic changes that play a role in the progression of canine
MCTs need to be identified in order to develop targeted
treatment strategies in those MCTs that lack ITD c-KIT
mutations. However, additional domains of the c-KIT
proto-oncogene still need to be evaluated for the presence
of activating mutations in canine MCTs. One area of par-
ticular interest is, the extracellular ligand-binding domain
where mutations have been identified in exon 8 of human
familial mastocytosis and GIST patients [49] and exon 9
of human GIST patients [48,50,51].
Additional work from our laboratory has shown a correla-
tion between ITD c-KIT mutations and the aberrant local-
ization of KIT in canine MCTs [36]. These results suggest
that ITD c-KIT mutations may lead to the aberrant cyto-
plasmic localization of KIT in at least a subset of canine
MCTs. Despite this correlation between ITD mutations
and aberrant KIT localization, we have identified some
MCTs that have aberrant KIT localization, but do not have
ITD c-KIT  mutations [36]. We hypothesized that point
mutations in exon 17 of the c-KIT proto-oncogene, similar
to those seen in human patients with mastocytosis, are
responsible for the aberrant KIT localization in MCTs
without ITD c-KIT mutations. However, in this study we
did not find any mutations in exon 17 of the c-KIT proto-
oncogene in 18 canine cutaneous MCTs with aberrant KIT
localization. These results suggest that other changes to c-
KIT, such as mutations in other c-KIT domains, changes in
transcriptional regulation or alternative splicing, or other
cellular changes, such as changes in golgi processing or
intracellular trafficking may be responsible for aberrant
KIT localization and may therefore play a role in the pro-
gression of canine cutaneous MCTs.
Conclusion
In this study no kinase domain c-KIT  mutations were
found in any canine cutaneous MCT examined and there-
fore these mutations do not appear to play a significant
role in the progression of this disease. In accordance with
this data, exon 17 c-KIT mutations do not appear to be
responsible for aberrant KIT localization in canine MCTs
with aberrant KIT localization that lack ITD c-KIT muta-
tions. Due to the relatively low incidence of juxtamem-
brane domain c-KIT  mutations, and the lack of kinase
domain mutations in canine cutaneous MCTs, further
Schematic Diagram of Primer Design for Polymerase Chain  Reaction Figure 3
Schematic Diagram of Primer Design for Polymerase Chain 
Reaction. Forward and reverse primers (arrows) were 
designed in introns (black boxes) flanking exons 16, 17, 18, 
19, and 20 (white boxes).BMC Cancer 2006, 6:85 http://www.biomedcentral.com/1471-2407/6/85
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studies are necessary to identify additional factors and
genes that lead to the progression of canine cutaneous
MCTs. Although targeting constitutively activated KIT pro-
tein in canine MCTs offers great promise for the treatment
of canine MCTs [39,46], such a therapeutic approach may
not be justified for all MCTs. A significant number of
MCTs seem to have no alterations in the c-KIT  proto-
oncogene, and targeted inhibition of this gene will there-
fore have little or no effect on these tumors. Therefore,
additional studies need to be performed in order to deter-
mine other factors that may be involved in the progres-
sion of canine MCTs without ITD c-KIT  mutations in
order to identify potential targets in those tumors.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
JDW carried out the PCR amplification and sequencing of
this study, with technical assistance from Daniel Zemke,
Elizabeth Kruszewski, and Angela Sosin, and drafted the
manuscript.
MK participated in the design of the study and helped
draft the manuscript.
VYG participated in the design of the study, coordinated
the study and helped draft the manuscript.
All authors red and approved the final manuscript.
Acknowledgements
The authors would like to acknowledge Dr. Daniel Zemke, Elizabeth 
Kruszewski, and Angela Sosin for their technical assistance. Funding for this 
study was provided in part by the Companion Animal Fund of the College 
of Veterinary Medicine, Michigan State University. JDW is funded by NIH 
T-32 post-doctoral training grant number RR17189.
References
1. Yarden Y, Escobedo JA, Kuang WJ, Yang-Feng TL, Daniel TO, Trem-
ble PM, Chen EY, Ando ME, Harkins RN, Francke U, Fried VA, Ullrich
A, Williams LT: Structure of the receptor for platelet-derived
growth factor helps define a family of closely related growth
factor receptors.  Nature 1986, 323:226-232.
2. Yarden Y, Kuang W, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ,
Chen E, Schlessinger J, Francke U, Ullrich A: Human proto-onco-
gene c-kit: a new cell surface receptor tyrosine kinase for an
unidentified ligand.  EMBO 1987, 6:3341-3351.
Amino acid alignment of the kinase domain (exons 16–20) of canine and human KIT Figure 4
Amino acid alignment of the kinase domain (exons 16–20) of canine and human KIT. Canine and human amino acid alignments 
demonstrate a 99.5% identity between the phospho-transferase portion of the kinase domain of these species. Codon 816, 
which is commonly mutated in human mastocytosis patients (D816V; shaded residue) is also conserved in canine KIT.
Exon 16
748 G S Y I E R D V T P A I M E D D E L A L D L E D L L S F S Canine
745   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Human   
Exon 17
777   Y Q V A K G M A F L A S K N C I H R D L A A R N I L L T H 
774   . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Exon 18
806   G R I T K I C D F G L A R D I K N D S N Y V V K G N A R L 
803   . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   
835   P V K W M A P E S I F N C V Y T F E S D V W S Y G I F L W
832   . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Exon 19
864   E L F S L G S S P Y P G M P V D S K F Y K M I K E G F R M
861   . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Exon 20
893   L S P E H A P A E M Y D I M K T C W D A D P L K R P T F K  
890   . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
922   Q I V Q L I E K Q I S D S T N H 
919   . . . . . . . . . . . E . . . .
Amino Acid 
ResidueBMC Cancer 2006, 6:85 http://www.biomedcentral.com/1471-2407/6/85
Page 7 of 8
(page number not for citation purposes)
3. Chan PM, Ilangumaran S, La Rose J, Chakrabartly A, Rottapel R:
Autoinhibition of the KIT receptor tyrosine kinase by cysto-
lic juxtamembrane region.  Mol Cel Biol 2003, 23:3067-3078.
4. Nocka K, Majumder S, Chabot B, Ray P, Cervone M, Bernstein A, Bes-
mer P: Expression of c-kit gene products in known cellular tar-
gets of W mutations in normal and W mutant mice-
evidence for an impaired c-kit kinase in mutant mice.  Genes
Dev 1989, 3:816-826.
5. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A:
Expression of c-kit  receptor in normal and transformed
human nonlymphoid tissues.  Cancer Res 1992, 53:6139-6143.
6. Matsuda R, Takahashi T, Nakamura S, Sekido Y, Nishida K, Seto M,
Seito T, Sugiura T, Ariyoshi Y, Takahashi T, Ueda R: Expression of
the c-kit protein in human solid tumors and in corresponding
fetal and adult normal tissues.  Am J Pathol 1993, 142:339-346.
7. Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T,
Suzuki T, Seito T: Preferential localization of c-kit product in
tissue mast cells, basal cells of skin, epithelial cells of breast,
small cell lung carcinoma, and seminomas/dysgerminoma in
humans: immunohistochemical study on formalin-fixed, par-
affin-embedded tissues.  Virchows Arch 1994, 424:135-141.
8. Arber DA, Tamayo R, Weiss LM: Paraffin section detection of
the c-kit gene product (CD117) in human tissues: value in the
dagnosis of mast cell disorders.  Hum Pathol 1998, 29:498-504.
9. Huang E, Nocka K, Beler DR, Chu TY, Buck J, Lahm HW, Wellner D,
Leder P, Besmer P: The hematopoietic growth factor KL is
encoded by the Sl locus and is the ligand of the c-kit receptor,
the gene product of the W locus.  Cell 1990, 63:225-233.
10. Nocka K, Buck J, Levi E, Besmer P: Canidate ligand for the c-kit
transmembrane kinase receptor: KL, a fibroblast derived
growth factor stimulates mast cells and erythroid progeni-
tors.  EMBO 1990, 9:3287-3294.
11. Zsebo KM, Wypych J, McNiece IK, Lu HS, Smith KA, Karkare SB,
Sachdev RK, Yuschenkoff VN, Birkett NC, Williams LR, Satyagal VN,
Tung W, Bosselman RA, Mendiaz EA, Langley KE: Identification,
purification, and biological characterization of hematopoi-
etic stem cell factor from bull rat liver-conditioned medium.
Cell 1990, 63:195-201.
12. Zsebo KM, Williams DA, Geissler EA, Broudy VC, Martin FH, Atkins
HL, Hsu RY, Birkett NC, Okino KH, Murdock DC, Jacobsen FW, Lan-
gley KE, Smith KA, Takeishi T, Cattanach BM, Galli SJ, Suggs SV: Stem
cell factor is encoded at the Sl locus of the mouse and is the
ligand for the c-kit  tyrosine kinase receptor.  Cell 1990,
63:213-224.
13. Tsai M, Takeishi T, Thompson H, Langley KE, Zsebo KM, Metcalfe
DD, Geissler EN, Galli SJ: Induction of mast cell proliferation,
maturation and heparin synthesis by the rat c-kit  ligand,
stem cell factor.  Proc Ntl Acad Sci USA 1991, 88:6382-6386.
14. Columbo M, Horowitz EM, Botana LM, MacGlashan DW, Bochner
BS, Gillis S, Zsebo KM, Galli SJ, Lichtenstein LM: The human
recombinant c-kit receptor ligand, rhSCF, induces mediator
release from human cutaneous mast cells and enhances IgE-
dependent mediator release from both skin mast cells and
peripheral blood basophils.  J Immunol 1992, 149:599-608.
15. Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo KM, Zetter BR:
The c-kit receptor ligand functions as a mast cell chemoat-
tractant.  Blood 1992, 79:958-963.
16. Dastych J, Metcalfe DD: Stem cell factor induces mast cell adhe-
sion to fibronectin.  J Immunol 1994, 152:213-219.
17. Yee NS, Paek I, Besmer P: Role of kit-ligand in proliferation and
suppression of apoptosis in mast cells: basis for radiosensitiv-
ity of white spotting and steel mutant mice.  J Exp Med 1994,
179:1777-1787.
18. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U,
Sagahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y,
Kitamura Y, Kanakura Y: Identification of mutations in the cod-
ing sequence of the proto-oncogene c-kit in a human mast
cell leukemia cell line causing ligand-independent activation
of c-kit product.  J Clin Invest 1993, 92:1736-1744.
19. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S,
Suzuki Y, Metcalfe DD: Identification of a point mutation in the
catalytic domain of proto-oncogene c-kit in peripheral blood
mononuclear cells of patients who have mastocytosis with an
associated hematologic disorder.  Proc Ntl Acad Sci USA 1995,
92:10560-10564.
20. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding T, Duffy T, Jacobs
P, Tang LH, Modlin I: Somatic c-kit activating mutation in utri-
caria pigmentosa and aggressive mastocytosis: establish-
ment of clonality in a human mast cell neoplasm.  Nature
Genetics 1996, 12:312-314.
21. Tian Q, Frierson HF, Krystal GW, Moskaluk CA: Activating c-kit
gene mutations in human germ cell tumors.  Am J Pathol 1999,
154:1643-1647.
22. Sakuma Y, Sakuri S, Oguni S, Hironaka M, Saito K: Alterations of
the c-kit gene in testicular germ cell tumors.  Cancer Sci 2003,
94:486-491.
23. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S,
Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y,
Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function muta-
tions of c-kit in human gastrointestinal stromal tumors.  Sci-
ence 1998, 279:577-580.
24. Worobec AS, Semer T, Nagata H, Metcalfe DD: Clinical correlates
of the presence of Asp816Val c-kit mutation in the peripheral
blood mononuclear cells of patients with mastocytosis.  Can-
cer 1998, 83:2120-2129.
25. Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu S, Heitjan
D, Ma Y: Activating and dominant inactivating c-kit catalytic
domain mutations in distinct clinical forms of human masto-
cytosis.  Proc Ntl Acad Sci USA 1999, 96:1609-1614.
26. LaSota J, Jasinski M, Sarlomo-Rikala M, Miettinen M: Mutations in
exon 11 of c-kit  occur preferentially in malignant versus
benign gastrointestinal stromal tumors and do not occur in
leiomyomas or leioyosarcomas.  Am J Pathol 1999, 154:53-60.
27. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda
H, Kitamura Y: Effect of c-kit mutation on prognosis of gas-
trointestinal stromal tumors.  Cancer Res 1999, 59:4297-4300.
28. Brodey RS: Canine and feline neoplasia.  Adv in Vet Sci Comp Med
1970, 14:309-354.
29. Preister WA: Skin tumors in domestic animals. Data from 12
United States and Canadian colleges of veterinary medicine.
J Ntl Cancer Inst 1973, 50:457-466.
30. Finnie JW, Bostock DE: Skin neoplasia in dogs.  Australian Veteri-
nary Journal 1979, 55:602-604.
31. Rothwell TLW, Howlett CR, Middleton DJ, Griffiths DA, Duffs BC:
Skin neoplasms of dogs in Sydney.  Aust Vet J 1987, 64:161-164.
32. Misdorp W: Mast cells and canine mast cell tumors: a review.
Vet Q 2004, 26:156-169.
33. London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN:
Spontaneous canine mast cell tumors express tandem dupli-
cations in the proto-oncogene.  c-KIT 1999, 27:689-697.
34. Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH: Clus-
tering of activating mutations in c-KIT  's juxtamembrane
coding region in canine mast cell neoplasms.  J Invest Dermatol
1999, 112:165-170.
35. Zemke D, Yamini B, Yuzbasiyan-Gurkan V: Mutations in the jux-
tamembrane domain of c-KIT  are associated with higher
grade mast cell tumors in dogs.  Vet Pathol 2002, 39:529-535.
36. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH,
Kiupel M: The role of c-KIT  in tumorigenesis:evaluation in
canine cutaneous mast cell tumors.  Neoplasia  in press.
37. Downing S, Chien MB, Kaas PH, Moore PE, London CA: Prevalence
and importance of internal tandem duplications in exons 11
and 12 of c-KIT in mast cell tumors of dogs.  Am J Vet Res 2002,
63:1718-1723.
38. Jones CLR, Grahn RA, Chien MB, Lyons LA, London CA: Detection
of c-KIT mutations in canine mast cell tumors using fluores-
cent polyacrylamide gel electrophoresis.  J Vet Diagn Invest
2004, 16:95-100.
39. Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington
JM, London CA: Proof of target for SU11654: inhibition of KIT
phosphorylation in canine mast cell tumors.  Clin Cancer Res
2003, 9:5729-5734.
40. Reguera MJ, Rabanal RM, Puigdemont A, Ferrer L: Canine mast cell
tumors express stem cell factor receptor.  Am J Dermatopathol
2000, 22:49-54.
41. Webster JD, Kiupel M, Kaneene JB, Miller R, Yuzbasiyan-Gurkan V:
The use of KIT and tryptase expression patterns as prognos-
tic tools for canine cutaneous mast cell tumors.  Vet Pathol
2004, 41:371-377.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2006, 6:85 http://www.biomedcentral.com/1471-2407/6/85
Page 8 of 8
(page number not for citation purposes)
42. Preziosi R, Morini M, Sarli G: Expression of the KIT protein
(CD117) in primary cutaneous mast cell tumors of the dog.
J Vet Diagn Invest 2004, 16:554-561.
43. Patnaik AK, Ehler WJ, MacEwen EG: Canine cutaneous mast cell
tumor: morphologic grading and survival time in 83 dogs.  Vet
Pathol 1984, 21:469-474.
44. Banerjee SK, Makdisi WF, Weston AP, Mitchell SM, Campell DR:
Microwave-based DNA extraction from paraffin-embedded
tissue for PCR amplification.  BioTechniques 1995, 18:768-773.
45. Brouillette JA, Andrew JR, Venta PJ: Estimate of nucleotide diver-
sity in dogs with a pool-and -sequence method.  Mamm Genome
2000, 11:1079-1086.
46. Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington
JM, London CA: Inhibition of constitutively active forms of
mutant KIT by multitargeted indolinone tyrosine kinase
inhibitors.  Blood 2002, 15:585-593.
47. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Berweij J, Brown M,
Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A,
Glabbeke M, van Oosterom AT: Use of c-KIT /PDGFR muta-
tional analysis to predict the clinical response to imatinib in
patients with advanced gastrointestinal stromal tumours
entered on phase I and II studies of the EORTC Soft Tissue
and Bone Sarcoma Group.  Eur J Cancer 2004, 40:689-695.
48. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M,
Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ,
Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, Silberman
S, Dimitrijevic , Fletcher JA: Kinase mutations and imatinib
response in patients with metastatic gastrointestinal stro-
mal tumor.  J Clin Oncol 2003, 21:4342-4349.
49. Hartmann K, Wardelmann E, Ma Y, Merkelbach-bruse S, Preussner
LM, Carla W, Baldus SE, Heinicke T, Thiele J, Buettner R, Longley BJ:
Novel germline mutation of KIT associated with familial gas-
trointestinal stromal tumors and mastocytosis.  Gastroenterol
2005, 129:1042-1046.
50. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK,
Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CDM, Fletcher
JA: KIT activation is a ubiquitous feature in gastrointestinal
stromal tumors.  Cancer Res 2001, 61:8118-8121.
51. Penzel R, Aulmann S, Moock M, Schwarzbach M, Rieker RJ, Mechter-
sheimer G: The location of KIT and PDGFRA gene mutations
in gastrointestinal stromal tumours is site and phenotype
associated.  J Clin Pathol 2005, 58:634-639.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/85/prepub